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If all patients responded to treatment in a similar way, there would be little or no 
variability in outcomes within treatment groups. Experience suggests otherwise,
raising the question, what accounts for this variability in response? Some of the het-
erogeneity in response may be attributable to observed variables that are included as 
covariates in analyses (age, gender, dose, dosing schedule or missed doses, comorbidi-
ties); some may be the result of unobserved but potentially identiﬁ able factors, such 
as genetics. Still others may involve data that are collected as part of the trial but are
not explicitly included as covariates in analyses such as baseline levels of variables or 
changes in study variables. In this latter case, the cause of heterogeneity must be 
inferred from the data. Methods have been developed to aid in categorization of 
responders but these methods are not used to full advantage in trials and outcomes
studies. Factor mixture models are a combination of common factor and latent class 
analysis that can be used to explore unobserved population heterogeneity. Mixture 
models can be used to identify trial patients that exhibit within-class homogeneity yet
are themselves different categorically from other classes of patients; this method
enables identiﬁ cation of variables that may account for the categorical differentiation.
This session demonstrates the use of mixture models for uncovering such subgroups 
as hyper- or hypo-responders to treatment in the context of clinical trials. Examples 
from a clinical trial and a simulation study are presented to show how these subgroups
and their characteristics are detected. Other methods for exploring what personal
characteristics of trial enrolees inﬂ uence treatment response using logistic and polyto-
mous regression will also be demonstrated.
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OBJECTIVES: To compare different approaches to estimate incremental expenditures
using an example of estimating the direct cost of treating Otitis Media (OM) among
children in the US. METHODS: Three approaches; covariate matched case-control
(CM), probability matched case-control (PM), and the generalized linear regression 
(i.e., GLM with log-link and gamma variance function) with standard risk adjustment, 
were developed using the 2005 Medical Expenditure Panel Survey (MEPS) data. 
Children with OM (age 18 years; n  9,691) were identiﬁ ed using International 
Classiﬁ cation of Diseases (ICD)-9 diagnosis codes 381 or 382 for OM. All three ap-
proaches included age, sex, race, ethnicity, education, region, insurance, and number
of medications used (proxy for comorbidity) as covariates. For the CM method, OM
cases were matched with non-OM controls exactly on categorical variables and on the 
largest possible absolute difference (AD) of 0 (vs. 5) for the two continuous variables 
(age and education). For the PM method, the case-control match was obtained using
predicted probability of OM with an AD of 0.01 (vs. 0.0001). The estimated incre-
mental expenditures and the number of matched pairs obtained using the above 
approaches were compared. RESULTS: The number of matched pairs ranged from 907
children for CM with AD  0 to 1,664 children for PM with AD  0.01. In contrast, 
the GLM approach included the entire sample (n  9,691) for the analysis. Incremental
expenditures associated with OM using the CM method were lowest (median difference 
[MD] range: $197.68 to $213.98) followed by GLM approach (mean difference: 
$245.6) and highest using the PM method (MD: $275.89 and $299.79). The mean 
differences using the CM and PM methods varied widely. CONCLUSIONS: Based on
the relative ease in computing, use of the entire sample for analysis, and the consider-
ation for the distribution function of expenditure data, GLM with standard risk 
adjustment may be a preferred approach to estimate incremental expenditures.
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FINITE MIXTURE REGRESSIONS IN MODELING PRESCRIPTION DRUG
UTILIZATION AND PRESCRIPTION DRUG EXPENDITURES OF PATIENTS 
WITH REUMATOID ARTHRITIS (RA)
Kim J
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OBJECTIVES: Finite mixture regression models have been used to estimate skewed 
distributions. However, mixture models have not been broadly considered in outcomes 
research. This study examined whether mixture regressions gave a better ﬁ t to the 
data than regressions with single distribution when estimating prescription drug utili-
zation and prescription drug expenditures with high positive skewness. METHODS:
The Medical Expenditure Panel Survey which is a nationally representative survey 
with comprehensive information on health care use and spending was used to estimate 
prescription drug utilization and prescription drug expenditures of adult patients (q20 
years old) with RA in 2005. Poisson distributions to estimate prescription drug utiliza-
tion and gamma distributions to estimate prescription drug expenditures were consid-
ered. Bayesian information criteria (BIC) were used to compare regression models. 
RESULTS: A total of 4,546 patients with a diagnosis of RA (mean age: 60.3 years, 
female: 65.0%) were included in the study. Mean number of prescriptions was 31
(median: 21). Skewness and Kurtosis in number of prescriptions were 1.9 and 8.2,
respectively. Mean expenditure on prescription drugs was $2050.80 (median:
$1210.50). Skewness and Kurtosis in expenditure on prescription drug were 8.4 and 
170.4, respectively. After controlling demographic and clinical variables, a mixture
model with two Poisson distributions (BIC: 28,735) gave a better ﬁ t to the drug utiliza-
tion data than a model with a Poisson distribution (BIC: 114,339) and a negative 
binomial model (BIC: 38,559). A mixture model with two gamma distributions (BIC: 
35,806) gave a better ﬁ t to the drug expenditure data than a model with a gamma
distribution (BIC: 36,208). CONCLUSIONS: This study showed that mixture models
provided better ﬁ ts to the data with high positive skewness than regression models 
with single distribution when estimating the number of prescriptions and the prescrip-
tion drug expenditures of patients with RA.
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OBJECTIVES: To review the efﬁ cacy of instrumental variable models in addressing a
variety of assumption violations to ensure standard ordinary least squares estimates
are consistent. Instrumental variable models gained popularity in outcomes research 
because of their ability to consistently estimate the average causal effects even in the 
presence of unmeasured confounding. However, in order for this consistent estimation
to be achieved several conditions must hold. In this paper, we provide an overview of 
the instrumental variable approach, examine possible tests to check the prerequisite
conditions, and illustrate how weak instruments may produce inconsistent and inefﬁ -
cient results. METHODS: We use two instrumental variables and apply Shea’s partial
R-square method, the Anderson canonical correlation, and Cragg-Donald tests to 
check for weak instruments. Hall-Pexie tests are applied to see if any of these instru-
ments are redundant in the analysis. RESULTS: A total of 15,956 asthma patients
from a private payer data set were examined in this study. We used controller-reliever
copay ratio and physician/practice prescribing patterns as an instrument. We demon-
strated that the former was a weak and redundant instrument producing inconsistent
and inefﬁ cient estimates of the effect of treatment. The results were worse than the 
results from standard regression analysis. CONCLUSIONS: Despite the obvious 
beneﬁ t of instrumental variable models, the method should not be used blindly. Several
strong conditions are required for these models to work, and each of them should be 
tested. Otherwise, the results will be statistically worse than the results achieved by
simply using standard ordinary least squares.
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OBJECTIVES: Coronary heart disease (CHD) is associated with one-half of all car-
diovascular events in the US among working-age adults, with an estimated cost of 
$156.4 billion in 2008. Several lifestyle and treatment interventions are associated 
with reductions in CHD events and mortality. Our goal was to develop an interactive 
model based on rigorous analytic methods that would enable employers to assess, 
through the use of a simple interface, the expected occurrence of CHD events and
associated costs among covered employees and retirees with dyslipidemia. METHODS:
An analytic model framework was developed to estimate expected CHD events and 
costs from an employer perspective. Model inputs include demographics, presence of 
CHD risk factors, employment details (active vs. retired; full-time vs. part-time; 
salary), direct medical costs of CHD events, work-loss (disability insurance details,
worker replacement scenarios), and discount and medical cost inﬂ ation rates. Default
input parameter values are based on nationally-representative NHANES data, com-
mercial insurance claims data, and published literature. The model interface allows 
employers to modify default values to ﬁ t their population and to conduct sensitivity 
analyses. Prediction equations derived from NHANES data and Framingham risk 
equations are used along with employer data to predict the expected number of CHD 
events and the proportion achieving lipid goals. Employer costs are calculated based 
on the predicted number of events, medical costs per event, and indirect costs resulting 
from absenteeism. RESULTS: Model outputs include the percentage of employees/
retirees expected to reach lipid control targets, expected number of CHD events, and
total costs associated with CHD events (sum of direct and indirect costs). Employer-
speciﬁ c results are compared to national benchmarks. CONCLUSIONS: This interac-
tive model illustrates how pragmatic outcomes research can be converted into a 
transparent tool addressing serious health care budget issues that is readily understood
by a diverse set of corporate managers.
PMC45
EXTENDING RANDOM EFFECT MODELS TO CENSORED COST DATA
Baser O1, Yuce H2, Gust C3
1University of Michigan and STATinMED Research, Ann Arbor, MI, USA, 2STATinMED
Research and The City University of New York, Brooklyn, NY, USA, 3STATinMED Research, 
Ann Arbor, MI, USA
OBJECTIVES: Challenges in analyzing cost data include addressing skewness in cost
distributions, observed and unobserved heterogeneity across samples, and even more
challenging complexities due to censoring. We combined generalized random effect
